MDTC34 Stock Overview
Develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Medtronic plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$246.72 |
| 52 Week High | US$263.38 |
| 52 Week Low | US$191.14 |
| Beta | 0.85 |
| 11 Month Change | -1.31% |
| 3 Month Change | 0.88% |
| 1 Year Change | 28.82% |
| 33 Year Change | -23.50% |
| 5 Year Change | n/a |
| Change since IPO | 75.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| MDTC34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | -0.9% | 0.7% | -0.8% |
| 1Y | 28.8% | 15.0% | -2.9% |
Return vs Industry: MDTC34 exceeded the BR Medical Equipment industry which returned 14.8% over the past year.
Return vs Market: MDTC34 exceeded the BR Market which returned -1.7% over the past year.
Price Volatility
| MDTC34 volatility | |
|---|---|
| MDTC34 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in BR Market | 8.2% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: MDTC34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine MDTC34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 95,000 | Geoff Martha | www.medtronic.com |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products.
Medtronic plc Fundamentals Summary
| MDTC34 fundamental statistics | |
|---|---|
| Market cap | R$627.05b |
| Earnings (TTM) | R$24.93b |
| Revenue (TTM) | R$191.81b |
25.3x
P/E Ratio3.3x
P/S RatioIs MDTC34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDTC34 income statement (TTM) | |
|---|---|
| Revenue | US$33.00b |
| Cost of Revenue | US$11.41b |
| Gross Profit | US$21.58b |
| Other Expenses | US$17.29b |
| Earnings | US$4.29b |
Last Reported Earnings
Oct 25, 2024
Next Earnings Date
Feb 18, 2025
| Earnings per share (EPS) | 3.34 |
| Gross Margin | 65.41% |
| Net Profit Margin | 13.00% |
| Debt/Equity Ratio | 58.1% |
How did MDTC34 perform over the long term?
See historical performance and comparison